Skip to Main Content

Author Details

Jeeyun Lee
Samsung Medical Center, Sungkyunkwan University School of Medicine
2003
472
66
PMIDPaper TitleJournal TitlePublished Year
36379002Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.J Clin Oncol2023
37720428Tumor mutation burden in gastro-entero-pancreatic-neuroendocrine neoplasms.J Gastrointest Oncol2023
37553133The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer.J Gastric Cancer2023
38000030Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer.Sci Adv2023
37654198Impact of programmed death-ligand 1 (PD-L1) positivity on clinical and molecular features of patients with metastatic gastric cancer.Cancer Med2023
37744267Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer.Oncol Res2023
37499191Clinical Implication of <i>HER2</i> Aberration in Patients With Metastatic Cancer Using Next-Generation Sequencing: A Pan-Tumor Analysis.JCO Precis Oncol2023
37568657A Machine Learning Approach Using FDG PET-Based Radiomics for Prediction of Tumor Mutational Burden and Prognosis in Stage IV Colorectal Cancer.Cancers (Basel)2023
37674200Clinically conserved genomic subtypes of gastric adenocarcinoma.Mol Cancer2023
35681110A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer.Cancer Res Treat2023
37251949Xernaâ¿¢ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers.Front Oncol2023
37081749TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors.Cancer Med2023
37341658PIK3CA mutation subtype delineates distinct immune profiles in gastric carcinoma.J Pathol2023
37406106Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer.Clin Cancer Res2023
36533429Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.Jpn J Clin Oncol2023
36940261Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.Oncologist2023
36455365Five-gene signature for the prediction of response to immune checkpoint inhibitors in patients with gastric and urothelial carcinomas.Pathol Res Pract2023
36164943Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response.Cancer Res Treat2023
33980610Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial.Gut2022
35772045Oxaliplatin (3 months <i>v</i> 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07.J Clin Oncol2022
35411243Expression of SLC22A18 regulates oxaliplatin resistance by modulating the ERK pathway in colorectal cancer.Am J Cancer Res2022
35349370Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.J Clin Oncol2022
35377061Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer.Ann Surg Oncol2022
35342406Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing.J Oncol2022
35793874Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study.J Immunother Cancer2022
35790315Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.J Immunother Cancer2022
35657979Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.Clin Cancer Res2022
35553647Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors.Clin Cancer Res2022
36400106Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.Lancet Oncol2022
36483096MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer.Pathol Oncol Res2022
36002189Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study.J Immunother Cancer2022
36043394All-in-one microfluidic design to integrate vascularized tumor spheroid into high-throughput platform.Biotechnol Bioeng2022
36307405ESRP1-regulated isoform switching of LRRFIP2 determines metastasis of gastric cancer.Nat Commun2022
36068115First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma.J Am Acad Dermatol2022
35884869Clinical Significance of Preoperative Hematological Parameters in Patients with D2-Resected, Node-Positive Stomach Cancer.Biomedicines2022
34980153A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology.Mol Cancer2022
35281856Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm, phase-II trial.J Cancer2022
35038826Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study.Cancer Res Treat2022
35144967Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.Clin Cancer Res2022
34933901Early Tumor-Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer.Cancer Discov2022
34933155Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer.Eur J Cancer2022
34986867Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial.Genome Med2022
34793662Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy.Cancer Res Treat2022
34433583Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.Gut2022
34656759Evaluating Targeted Next-Generation Sequencing Assays and Reference Materials for NTRK Fusion Detection.J Mol Diagn2022
34510272The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors.J Cancer Res Clin Oncol2022
34120231Prediction of epithelial-to-mesenchymal transition molecular subtype using CT in gastric cancer.Eur Radiol2022
32970267Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors.Gastric Cancer2021
33494793Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial.Genome Med2021
33717226Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors.Ther Adv Med Oncol2021
  • 1 - 50 of 472

Recommended Authors

Zhixin Qiu
UPMC Hillman Cancer Center
Career Start Year 2012
Number of shared co-authors 0
Yang Shao
Nanjing Geneseeq Technology Inc.
Career Start Year 2012
Number of shared co-authors 0
Liang Cao
National Cancer Institute, National Institutes of Health
Career Start Year 2008
Number of shared co-authors 0
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 0
Bo Gao
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 3
Ashiq Masood
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Career Start Year 2008
Number of shared co-authors 1
Yin Guan
DHC Technologies Co. Ltd.
Career Start Year 2008
Number of shared co-authors 0
Kjetil Boye
Oslo University Hospital
Career Start Year 2007
Number of shared co-authors 0
Iacopo Petrini
University of Pisa
Career Start Year 2006
Number of shared co-authors 0
John Paul Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 7
Sadakatsu Ikeda
Tokyo Medical and Dental University Hospital
Career Start Year 2006
Number of shared co-authors 4
Li Liu
Central South University
Career Start Year 2006
Number of shared co-authors 0
Rodrigo Dienstmann
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus
Career Start Year 2006
Number of shared co-authors 9
Celina Ang
Tisch Cancer Institute, Mount Sinai Hospital
Career Start Year 2005
Number of shared co-authors 4
Li Liu
College of Big Data & Software Engineering, Chongqing University
Career Start Year 2005
Number of shared co-authors 4
Fan Zhang
Huaihe Hospital of Henan University
Career Start Year 2004
Number of shared co-authors 0
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 0
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 4
Wei Zhang
Children's Hospital, Zhejiang University School of Medicine
Career Start Year 2001
Number of shared co-authors 1
Manish A Shah
Weill Cornell University
Career Start Year 2000
Number of shared co-authors 6
Timo Gaiser
Institut fur Pathologie, Universitatsmedizin Mannheim
Career Start Year 2000
Number of shared co-authors 1
Antonio Cubillo
Hospital HM Universitario Sanchinarro
Career Start Year 1997
Number of shared co-authors 2
Dong Lin
Fujian Medical University Cancer Hospital and Fujian Cancer Hospital
Career Start Year 1996
Number of shared co-authors 1
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 8
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 0
Tatsuhiro Shibata
Kurume University School of Medicine
Career Start Year 1993
Number of shared co-authors 0
Hideki Ueno
National Defense Medical College
Career Start Year 1993
Number of shared co-authors 1
Paul T Fanta
University of California San Diego Moores Cancer Center
Career Start Year 1992
Number of shared co-authors 8
Michael Allg??uer
Institute of Pathology, Heidelberg University Hospital
Career Start Year 1991
Number of shared co-authors 0
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 5

Collaborators

Joon Oh Park
Samsung Medical Center, Sungkyunkwan University School of Medicine
Co-authored papers 202
Sung Tae Kim
Busan Paik Hospital, Inje University
Co-authored papers 184
Kyoung-Mee Kim
Seoul National University College of Medicine
Co-authored papers 151
Min Gew Choi
Research Institute, National Cancer Center
Co-authored papers 42
Sun Young Kim
Asan Medical Center, University of Ulsan College of Medicine
Co-authored papers 23
Kyung Kim
Samsung Medical Center, Sungkyunkwan University School of Medicine
Co-authored papers 22
Woong-Yang Park
Samsung Genome Institute, Samsung Medical Center
Co-authored papers 22
Nayoung K D Kim
Samsung Genome Institute, Samsung Medical Center
Co-authored papers 12
Young Mog Shim
Samsung Medical Center, Sungkyunkwan University School of Medicine
Co-authored papers 12
Do-Hyun Nam
Samsung Medical Center, Sungkyunkwan University School
Co-authored papers 10
Sung Wook Seo
Samsung Medical Center, Sungkyunkwan University
Co-authored papers 9
Siraj M Ali
Foundation Medicine
Co-authored papers 8
Taehyang Lee
Samsung Medical Center, Sungkyunkwan University School of Medicine
Co-authored papers 7
Jusun Kim
Samsung Medical Center, Sungkyunkwan University School of Medicine
Co-authored papers 7
Vincent A Miller
Injury Prevention Research Center, University of North Carolina
Co-authored papers 7
Hee Jin Cho
Touro College of Osteopathic Medicine
Co-authored papers 7
AmirAli Talasaz
University of California San Diego Moores Cancer Center
Co-authored papers 6
Jeffrey S Ross
Foundation Medicine
Co-authored papers 6
Jason K Sa
Korea University, College of Medicine
Co-authored papers 6
Hyo Jin Kim
Department of Food Bioengineering, Jeju National University
Co-authored papers 6
Byong Chang Jeong
Samsung Medical Center, Sungkyunkwan University School of Medicine
Co-authored papers 5
Kyunga Kim
Co-authored papers 5
Jeong-Won Lee
Samsung Medical Center, Sungkyunkwan University School of Medicine
Co-authored papers 4
Kyu-Tae Kim
Ajou University
Co-authored papers 4
Adam J Bass
Co-authored papers 4
TaeJin Ahn
Co-authored papers 4
Jong-Won Kim
Samsung Medical Center, Sungkyunkwan University School of Medicine
Co-authored papers 4
Rebecca Nagy
Guardant Health Inc.
Co-authored papers 3
Joon Seol Bae
Research Institute of Future Medicine, Samsung Medical Center
Co-authored papers 3
Andrey Loboda
Merck & Co., Inc.
Co-authored papers 3
Release 1.2